23794-13-0

Basic information

• Product Name: 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone
• Synonyms: 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone;5-(2-Bromoacetyl)-2-chloropyridine;2-bromo-1-(6-chloro-3-pyridinyl)Ethanone
• CAS NO: 23794-13-0
• Molecular Formula: C₇H₅BrClNO
• Molecular Weight: 234.4777
• Mol File: 23794-13-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 79-80℃
• Boiling Point: 330.9 °C at 760 mmHg
• Flash Point: 153.9 °C
• Appearance: /
• Density: 1.683
• Vapor Pressure: 0.000161mmHg at 25°C
• Refractive Index: 1.589
• PKA: -2.60±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone(23794-13-0)
• EPA Substance Registry System: 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone(23794-13-0)

Safety Data

• Hazardous Substances Data: 23794-13-0(Hazardous Substances Data)

Usage

General Description

2-Bromo-1-(6-chloropyridin-3-yl)-ethanone is a chemical compound with the molecular formula C7H6BrClNO. It is a yellow solid with a molecular weight of 230.48 g/mol. 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone is used in various pharmaceutical and agricultural applications, including as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a reagent in organic synthesis and in the manufacture of other chemical compounds. 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone is a versatile compound with a range of potential industrial and research applications.

InChI:InChI=1/C7H5BrClNO/c8-3-6(11)5-1-2-7(9)10-4-5/h1-2,4H,3H2

Upstream product

• 55676-22-7 3-acetyl-6-chloropyridine 
• 5006-66-6 6-hydroxynicotinic acid 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 

Downstream Products

• 191596-45-9 N-[1-(3,4-dimethoxy-phenyl)-2-phenylethyl]-2-hydroxy-2-(2-chloropyrid-5-yl)-ethylamine 
• 1350522-25-6 C₁₃H₁₀ClNO₂ 
• 1350522-29-0 C₁₅H₁₅ClN₂O₂ 
• 1350522-32-5 C₁₄H₁₂ClNO₃ 
• 1350522-30-3 C₁₅H₁₂ClNO₄ 
• 1350522-24-5 C₁₃H₉BrClNOS 
• 1350522-05-2 C₁₃H₉BrClNO₂ 
• 1350522-26-7 C₁₃H₉ClFNO₂ 
• 1350522-27-8 C₁₃H₉BrClNO₂ 
• 1350522-33-6 C₁₄H₉ClF₃NO₂ 
• 1350522-23-4 C₁₈H₁₇BrN₄O₂ 
• 1350522-22-3 C₁₉H₁₃BrClNO₃ 
• 1350522-21-2 C₁₆H₁₇BrN₂O₂ 
• 1350522-20-1 C₁₆H₁₅BrN₂O₂ 

Relevant articles and documents

Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors

Autotaxin (ATX) is a secreted enzyme playing a major role in the production of lysophosphatidic acid (LPA) in blood through hydrolysis of lysophosphatidyl choline (LPC). The ATX-LPA signaling axis arouses a high interest in the drug discovery industry as it has been implicated in several diseases including cancer, fibrotic diseases, and inflammation, among others. An imidazo[1,2-a]pyridine series of ATX inhibitors was identified out of a high-throughput screening (HTS). A cocrystal structure with one of these compounds and ATX revealed a novel binding mode with occupancy of the hydrophobic pocket and channel of ATX but no interaction with zinc ions of the catalytic site. Exploration of the structure-activity relationship led to compounds displaying high activity in biochemical and plasma assays, exemplified by compound 40. Compound 40 was also able to decrease the plasma LPA levels upon oral administration to rats.

ACETYLENIC MICROBIOCIDES

Compounds of formula (I), wherein the other substituents HetAr, A', R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in claim 1, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.

HETEROCYCLIC AMINE DERIVATIVES

The present invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, nitro, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl, -O-CH2-C3-6-cycloalkyl, -O-(CH2)2-O-lower alkyl, S(O)2CH3, SF5, -C(O)NH-lower alkyl, phenyl, -O-pyrimidinyl, optionally substituted by lower alkoxy substituted by halogen, or is benzyl, oxetanyl or furanyl; m Ar is aryl or heteroaryl, selected from the group consisting of phenyl, naphthyl, pyrimidinyl, pyridinyl, benzothiazolyl, quinolinyl, quinazolinyl, benzo[d][1.3]dioxolyl, 5,6,7,8- tetrahydro-quinazolinyl, pyrazolyl, pyrazinyl, pyridazinyl, or 1,3,4-oxadiazolyl; Y is a bond, -CH2-, -CH2CH2-, -CH(CF3)- or -CH(CH3)-; R2 is hydrogen or lower alkyl; A is CR or N; and R is hydrogen, cyano, halogen or lower alkyl; R' is hydrogen or halogen; with the proviso that when R' is halogen, then A is CH; B is CH or N; n is 0, 1 or 2; X is a bond, -CH2- or -O-; pharmaceutical active acid addition salts thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.